论文部分内容阅读
目的研究再灌注期使用血管内皮生长因子单抗(Vascular endothelial growth factor monoclonal antibody,简称VEGFmAb)对大鼠肝缺血再灌注损伤的影响。方法将SD大鼠18只分为两组(每组n=9)。C组:实验对照组,常规行肝缺血再灌注损伤实验;V组:VEGFmAb处理组:在再灌注期使用血管内皮生长因子单抗。于术后2h、24h分别取血测肝功能,术后24h切取缺血肝叶检测热休克蛋白(heat shock protein 70,简称HSP70)RT-PCR表达、肝病理组织学改变,观察生存状态1周。结果与C组比较,V组HSP70的RT-PCR表达未见明显改变;V组ALT、AST在术后明显下降,肝病理组织学改变有所减轻,1周生存率提高(55.56%vs0)。结论再灌注期使用VEGFmAb有助于减轻大鼠对缺血再灌注损伤,改善预后。
Objective To investigate the effect of vascular endothelial growth factor monoclonal antibody (VEGF mAb) on hepatic ischemia-reperfusion injury during reperfusion in rats. Methods 18 SD rats were divided into two groups (n = 9 in each group). Group C: experimental control group, conventional liver ischemia-reperfusion injury test; Group V: VEGFmAb-treated group: Vascular endothelial growth factor monoclonal antibody was used during reperfusion. The liver function was measured at 2h and 24h after operation, and the expression of heat shock protein 70 (HSP70) was detected by RT-PCR at 24 hours after operation. The histopathological changes of liver were observed and the survival status was observed for 1 week . Results Compared with group C, there was no significant change in RT-PCR expression of HSP70 in group V; ALT and AST in group V were significantly decreased after operation, histological changes of liver pathology were alleviated, and the survival rate of one week was improved (55.56% vs0). Conclusion The use of VEGFmAb during reperfusion may help to reduce the damage of ischemia-reperfusion and improve the prognosis of rats.